PROVECTUS ANNOUNCES PV-10'S ASSESSMENT…
Xenotech’s State-of-the-art Study Design Strengthens Safety Data For Efficacious Anti-Cancer Agent
Experts from XenoTech, LLC successfully collaborated with researchers from Provectus Biopharmaceuticals, Inc., to determine the potential of Rose Bengal (the cancer formulation of a stain) to reveal harmful drug-drug interactions. Not satisfied with conventional, often inaccurate methods of in vitro testing, XenoTech designed highly customized and validated studies that assessed the risk of Rose Bengal to cause drug-drug interactions in humans. The validated results of XenoTech’s rapid assay development determined that the risk of clinically relevant drug-drug interactions with Rose Bengal is low—ultimately strengthening patient safety data and improving clinical trial design for the promising anti-cancer agent.
The FDA guidance for the industry on drug-drug interactions requires an in vitro assessment of the potential liability for a new drug to engender drug-drug interactions. These experiments are important because they provide the basis for safe, rational clinical trial design and are important determinants toward the ultimate goal, which is patient safety."
"We are very pleased with the expertise shown by our scientists. Rose Bengal presented a unique challenge, but we rose up to meet that challenge and showed what XenoTech, as a company, is all about. Our customers get rapid results, but they also receive the context to be assured that those results will be meaningful in their development programs."